Canopy Growth’s move into coffee market gets thumbs up at Echelon

Marijuana stocks have been less than perky of late, but Echelon Wealth Partners analyst Russell Stanley thinks Canopy Growth Corp’s (TSX:WEED) foray into the coffee market is one that underscores its leadership role in the space.

This morning, Canopy announced it had entered into a licensing agreement with Swiss-based hemp company Isodiol International Inc., that will allow Canopy to manufacture and distribute Isodiol “Pot-O-Coffee” and “Pot-O-Tea” marijuana-infused single-serve K-Cup products in Canada and other market.

“This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world,” said Isodiol CEO Marcos Agramont. “We will continue to develop our Pot-O-Coffee product lines with ready-to-drink and cold-brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence.”

Stanley say that while Canopy is making this deal in advance of actually be allowed to sell such products in Canada and many other markets, he believes it is the kind of forward thinking move that puts the company at the head of the pack in its space.

“(Canopy’s) market leadership continues with a pre-emptive strike into ingestible products,” the analyst says. “Canadian laws do not yet permit the manufacture and sale of cannabis-infused products, though as noted in the press release, WEED expects them to be legalized in the near future. We agree, and we view this initiative as evidence of continued market leadership by Canopy.”

In a research update to clients today, Stanley maintained his “Buy” rating and one-year price target of $14.00 on Canopy Growth Corp., implying a return of 67 per cent at the time of publication.

Stanley thinks Canopy will generate Adjusted EBITDA of negative $4.8-million on revenue of $127.9-million in fiscal 2018. He expects those numbers will improve to EBITDA of positive $32.0-million on a topline of $278.7-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: weed
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

1 day ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

1 day ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

1 day ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

2 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago